
Xynovir300 mg
Incepta Pharmaceuticals Ltd.
Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI) used in the following clinical settings: Established / FDA-approved uses Treatment of HIV-1 infection: Tenofovir…
Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI) used in the following clinical settings:
For the HIV-1 treatment and HIV PrEP indications, Tenofovir Disoproxil Fumarate must always be given as part of a complete antiretroviral regimen together with other agents; it must never be used as HIV monotherapy, since this risks development of viral resistance.
Tenofovir Disoproxil Fumarate is used off-label in some prevention-of-mother-to-child-transmission (PMTCT) protocols for pregnant women living with HIV, under specialist guidance, and in some settings as part of post-exposure prophylaxis (PEP) regimens.
Tenofovir Disoproxil Fumarate is administered orally, generally once daily, with or without food (though absorption is improved when taken with food, especially a high-fat meal). The dose depends on the indication, age, body weight, and renal function.
| Indication | Usual adult dose |
|---|---|
| HIV-1 infection (in combination with other antiretrovirals) | 300 mg once daily |
| HIV pre-exposure prophylaxis (PrEP), combined with emtricitabine | 300 mg once daily |
| Chronic hepatitis B infection | 300 mg once daily |
For HIV-1 treatment, Tenofovir Disoproxil Fumarate may be used in pediatric patients weighing at least 10 kg, with weight-band-based tablet or oral-powder dosing determined by a specialist. For chronic hepatitis B, use in pediatric patients is generally reserved for those aged 12 years and older weighing at least 35 kg, dosed at 300 mg once daily; safety and efficacy in younger children for the hepatitis B indication have not been fully established in all age groups. See Use in Special Populations and Pediatric Uses for further detail.
| Creatinine clearance | Adjusted dosing interval |
|---|---|
| ≥50 mL/min | 300 mg every 24 hours (standard) |
| 30–49 mL/min | 300 mg every 48 hours |
| 10–29 mL/min | 300 mg approximately twice weekly (every 72–96 hours), under close medical supervision |
| <10 mL/min, not on dialysis | Not recommended; no dosing recommendation established |
| On hemodialysis | 300 mg every 7 days, administered after completion of a dialysis session |
Renal function should be assessed before starting Tenofovir Disoproxil Fumarate and monitored periodically during treatment; see Precautions and Warnings.
If a dose of Tenofovir Disoproxil Fumarate is missed, it should be taken as soon as remembered on the same day; if it is almost time for the next dose, the missed dose should be skipped rather than doubling up. Maintaining consistent, uninterrupted dosing is important for treatment effectiveness and to reduce the risk of viral resistance.
Common and clinically important side effects of Tenofovir Disoproxil Fumarate include:
Patients should seek medical attention promptly for symptoms such as unusual muscle pain, difficulty breathing, marked fatigue, decreased urination, or swelling of the legs/ankles while taking Tenofovir Disoproxil Fumarate.
Tenofovir Disoproxil Fumarate is contraindicated in patients with known hypersensitivity to Tenofovir Disoproxil Fumarate, tenofovir, or any component of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.